Author

A. El kaoutari

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cancer Biology· 3

Signature Assays, Organisms & Methods

Click to filter · or open tag

Assay:bulk RNA-seq· 2 Research Focus:cancer & tumor microenvironment· 2 Approach:experimental assay· 2 Organism:human· 2 Research Focus:cell signaling & trafficking· 1 Research Focus:cell type annotation· 1 Research Focus:drug response / drug discovery· 1 Assay:metabolomics· 1

Frequent Co-Authors

A. Frances· 1 shared A. Lumeau· 1 shared A. Mathison· 1 shared A. Nevot· 1 shared C. Johnson· 1 shared C. L. Pin· 1 shared C. Lopez· 1 shared C. Ribeyre· 1 shared

Activity by Year

2021-2023 · peak 2/yr

Co-Author Collaboration Network

10 top collaborators · 16 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

1 shared paperCancer Biology

A. Frances

Mutual co-authors in cluster

Author profile →

3 papers

Recent·Most cited

EZH2 deletion does not impact acinar cell regeneration but restricts progression to pancreatic cancer in mice

E. Jaune-Pons, X. Wang, F. Mousavi, A. El kaoutari, K. Berger, C. Johnson, M. Martin, S. Aggarwal, S. Brar, K. Muhammad, P. Shooshtari, A. Mathison, N. Dusetti, R. Urrutia, G. Lomberk, C. L. Pin

This study shows EZH2 deletion in adult acinar cells does not block regeneration but limits PDAC progression by altering the tumor microenvironment and differentiation.

bioRxiv · Sep 25, 2023 · PreprintCancer Biology

Cytidine deaminase protects pancreatic cancer cells from replicative stress and drives resistance to DNA-targeting drugs

A. Lumeau, N. Bery, A. Frances, M. Gayral, C. Ribeyre, C. Lopez, A. Nevot, A. El kaoutari, G. Labrousse, M. Madrid-Mencia, M.-J. Pillaire, V. Pancaldi, V. Bergoglio, N. J. V. Dusetti, J.-S. Hoffmann, , P. Cordelier

This study shows that Cytidine deaminase (CDA) protects pancreatic cancer cells from replication stress and contributes to resistance against DNA-targeting drugs.

bioRxiv · Oct 23, 2021 · PreprintCancer Biology

Metabolomic profiling of pancreatic adenocarcinoma reveals fundamental clinical features

J. L. IOVANNA, A. El kaoutari, N. Fraunhoffer, O. Hoare, C. Teyssedou, O. Gayet, J. Roques, G. A. Lomberk, R. A. Urrutia, N. J. Dusetti

This study identifies a metabolic signature in pancreatic adenocarcinoma that predicts clinical outcomes and drug resistance, suggesting metabolic targeting as a therapeutic strategy.

bioRxiv · Feb 1, 2021Cancer Biology